Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-015
jRCT2021260021Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MK-1084 and durvalumab with Placebo and durvalumab (2 arms). Primary endpoint: Progression-free survival. Started Sep 2026; status: recruiting.
02
Drugs
calderasibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021260021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260021.